Daniel Podolsky

Mar 18, 2015

Agilent Technologies has appointed Daniel Podolsky to its board, increasing its size to 10 members. His appointment becomes effective in July. Podolsky is the president of the University of Texas Southwestern Medical Center. Previously, he served as chief academic officer and the faculty dean of academic programs for Partners Health System, as well as the Mallinckrodt Professor of Medicine at Harvard Medical School and chief of gastroenterology at Massachusetts General Hospital.

More Like This

Jul 26, 2017

Rohit Khanna

Waters said in a filing with the US Securities and Exchange Commission this week that Rohit Khanna has resigned from his position as SVP, Applied Technology, effective July 21, 2017. Khanna will continue to serve as an SVP of the company and as a member of the firm's executive committee until his retirement on Dec. 31, 2017. 

Jul 26, 2017

Scott Howell

Tenet Diagnostics has appointed Scott Howell its CMO. He was most recently executive medical director at Heritage Provider Network. He also continues to practice at Kaiser Permanente Los Angeles Medical Center in the addiction medicine department. He was previously national senior medical director and chief medical officer Network and Population Health, Optim Insight, regional CMO Northeast region of Americhoice, and national medical director of managed care for AIDS Healthcare Foundation. 

Jul 26, 2017

Gene DeFelice, Alexandra Snyder

Adaptive Biotechnologies has appointed Gene DeFelice to senior vice president and general counsel and Alexandra Snyder to translational medicine lead for Adaptive Research.

DeFelice has served as general counsel for several public healthcare and technology companies, including as primary counsel at Roche Diagnostics. He will join Adaptive's executive team to implement a legal infrastructure for clinical applications of next-generation sequencing technologies.

Snyder has joined Adaptive from Memorial Sloan Kettering Cancer Research Center where she specialized in tumor immunogenomics and response to checkpoint blockade immunotherapy.  

Jul 24, 2017

Kieran Murphy, Stephen Kanovsky

Kieran Murphy has resigned from the board of NeoGenomics following his appointment as president and CEO of GE Healthcare. NeoGenomics said in a document filed with the US Securities and Exchange Commission that Murphy resigned due to the time demands of his new job, and added that it has appointed Stephen Kanovsky to fill Murphy's position on the board. He is general counsel of GE unit Global Innovation of GE Healthcare.

Jul 21, 2017

Thomas Loewald

Thomas Loewald, senior vice president and chief commercial officer at Thermo Fisher Scientific since early 2016, will resign from the company, effective September 1. He joined the firm's Explosives Detection business in 2002 and held various positions over the years, including senior vice president and president of Laboratory Products. Prior to that, he was vice president of sales and marketing for Tyco International.

Jul 20, 2017

Mark Stevenson

Mark Stevenson has been promoted to executive vice president and chief operation officer of Thermo Fisher Scientific, effective August 1. In his new role, he will oversee operations of the company's Laboratory Products and Analytical Instruments businesses, in addition to the Life Sciences Solutions business. Since 2014, when Thermo Fisher acquired Life Technologies, Stevenson has been executive vice president and president of Life Sciences Solutions. Prior to that, he was president and chief operating officer of Life Technologies, and before that, he was president and COO of Applied Biosystems.

Jul 19, 2017

Hans Bishop

Hans Bishop has been elected to Agilent's board of directors. Bishop is cofounder, president, and CEO of Juno Therapeutics, a Seattle-based biopharmaceutical company. He has also held a range of executive positions in the pharmaceutical industry, including as COO at Dendreon; president of Specialty Medicine at Bayer Healthcare; and global commercial head for Chiron.

Jul 19, 2017

Daniel Sikkema

Quanterix has appointed Daniel Sikkema as vice president of acclerator services for the company's new Simoa Accelerator Lab, a dedicated environment for biomarker research, custom assay development, and clinical sample testing. Sikkema will work to expand the reach of Quanterix's Accelerator Lab services in neurology, oncology, immuno-oncology, infectious disease, inflammatory diseases, and other therapeutic areas. He has previously worked at Frontage Lab, Bristol-Myers Squibb, Wyeth, Merck, Sanofi Pasteur, and GlaxoSmithKline.

Jul 17, 2017

Stephen Pereira

Stephen Pereira has been appointed to Immunovia's scientific advisory board. Pereira is a professor of hepatology and gastroenterology at University College London and is an honorary consultant in pancreaticobiliary medicine at UCL Hospitals and the Royal Free Hospital. 

Jul 17, 2017

Daniel MacArthur

The American Society of Human Genetics has named Daniel MacArthur as the first recipient of its Early Career Award. He is an assistant professor in the Analytic and Translational Genetics Unit at Massachusetts General Hospital and Harvard Medical School and the co-director of the Medical and Population Genetics Program at the Broad Institute. The new award, which comes with $10,000 in prize money, recognizes contributions of genetics and genomics scientists in the first 10 years of their careers as independent investigators. MacArthur and his colleagues developed the Exome Aggregation Consortium (ExAC) database and website and its successor, the Genome Aggregation Database (gnomAD). He also published many scientific articles on identifying genes associated with rare diseases, in particular muscular disorders.

Jul 13, 2017

Mary Thistle

Enterome has appointed Mary Thistle to its board of directors as a non-executive director. Thistle currently serves as chief operating officer at Dimension Therapeutics, and has also served as senior VP of Business Development at Cubist Pharmaceuticals. Prior to joining Dimension in 2015, Thistle held leadership positions at ViaCell. In addition to developing therapeutic products for rare and metabolic liver diseases, Enterome also develops diagnostics to support therapies in microbiome-related diseases such as inflammatory bowel disease and cancer.

Jul 12, 2017

Arthur Beaudet

The American Society of Human Genetics has named Arthur Beaudet the recipient of this year's Victor A. McKusick Leadership Award. The award recognizes individuals whose "professional achievements have fostered and enriched the development of human genetics as well as its assimilation into the broader context of science, medicine, and health." Beaudet, who will receive the award along with a $10,000 prize at the ASHG annual meeting in October, is the Henry and Emma Mayer Professor in the Department of Molecular and Human Genetics and the Department of Pediatrics at Baylor College of Medicine. He is a member of the National Academy of Medicine and the National Academy of Sciences and has received several other awards for his work. Beaudet has published more than 350 articles in the scientific literature. 

Jul 12, 2017

Kári Stefánsson

The American Society of Human Genetics has named Kári Stefánsson the winner of this year's William Allan Award, a prize established in 1961 that recognizes a scientist for "substantial and far-reaching scientific contributions to human genetics." Stefánsson is the founder of Iceland's Decode Genetics, which has conducted a large-scale population genetics research project in Iceland. He has published more than 500 articles in the scientific literature and has received several awards for his work, including the European Society of Human Genetics Award in 2009.

Jul 07, 2017

Matthias Raquet

Oneservice, a Swiss company offering complete managed service solutions, consulting, and learning for the life science, diagnostics, and medical device industries, has appointed Matthias Raquet as CEO. Raquet joins Oneservice from Qiagen, where he has worked since 2001, most recently as vice president and head of global service solutions and global customer management. Prior to Qiagen he worked in various management roles at Amersham Pharmacia.

Jul 06, 2017

Steven Kanner

Caribou Biosciences has appointed Steven Kanner as CSO. Kanner has more than 25 years of experience in drug discovery and development. He previously served in various research leadership roles at Bristol-Myers Squibb, Astex Pharmaceuticals, and Agensys/Astellas Pharma. Most recently, he served as vice president of discovery biology at Arrowhead Pharmaceuticals.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.